# EMERGING-CTONG 1103 (NCT01407822)

> Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: erlotinib
- Indication: stage IIIA-N2 EGFR-mutant non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01407822
- Phase: PHASE2, PHASE3
- Status: UNKNOWN
- Sponsor: Guangdong Association of Clinical Trials
- Conditions: Non-small Cell Lung Cancer
- Interventions: Erlotinib; Gemcitabine/cisplatin
- Enrollment: 72
- Primary outcome: The objective response rate (ORR) in neoadjuvant treatment

## Indexed commentary on EMERGING-CTONG 1103 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=emerging-ctong-1103-nct01407822